Author:
Cascinu S,Berardi R,Salvagni S,Beretta G D,Catalano V,Pucci F,Sobrero A,Tagliaferri P,Labianca R,Scartozzi M,Crocicchio F,Mari E,Ardizzoni A
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. A'Hearn B (2004) A restricted maximum likelihood estimator for truncated height samples. Econ Hum Biol 2(1): 5–19
2. Andre T, Bensmaine MA, Louvet C, Francois E, Lucas V, Desseigne F, Beerblock K, Bouche O, Carola E, Merrouche Y, Morvan F, Dupont-Andre G, de Gramont A (1999) Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17(11): 3560–3568
3. Baselga J, Arteaga CL (2005) Critical update and emergine trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23: 2445–2459
4. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6: 2053–2063
5. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn Jr WD, Morse D, Abraham S, Rahman A, Liang C, Lostritto R, Baird A, Pazdur R (2004) United States Food and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10: 1212–1218
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献